However, recent small short - term studies have revealed the visual benefits of eye injections of medications that block a chemical signal that stimulates blood vessel growth, known
as vascular endothelial growth factor (VEGF).
A marker in bile known
as vascular endothelial growth factor (VEGF) plays an important role in the growth of cancerous tumors according to new research presented at the 78th Annual Scientific Meeting of the American College of Gastroenterology.
And they incorporated into the gel a protein known
as vascular endothelial growth factor (VEGF), which encourages the growth of blood vessels into the transplanted cells.
Not exact matches
The cannabinoids inhibited the expression of several genes critical to angiogenesis known
as the VEGF (
vascular endothelial growth factor) pathway.
They focused towards this end on the
vascular growth factor Angiopoietin - 2, which is produced by
endothelial cells and does not just control angiogenesis, but acts
as a key responsiveness
factor for
endothelial cells.
They then turned to neurochemical studies, including lactate, glutamate and glutamine metabolism, effects on the hypothalamic - pituitary - adrenal (HPA) axis through cortisol secretion, and neurotrophins such
as brain - derived neurotrophic
factor (BDNF), insulin - like
growth factor 1 (IGF - 1), and
vascular endothelial growth factor (VEGF).
The pioneering work of Dr. Aiello helped demonstrate the role of
vascular endothelial growth factor (VEGF) in diabetic retinopathy and other retinal disorders,
as well
as the therapeutic potential of VEGF inhibitors in these conditions.
For the analysis of mRNA levels for asparagine synthetase (ASNS), CHOP (CCAAT / enhancer - binding protein homologous protein),
vascular endothelial growth factor (VEGF), glucose transporter 1 (Slc2a1) and monocarboxylate transporter 4 (Slc16a3), RT - PCR
as well
as qPCR were used.
From these cell based and clinical studies, we have developed important mechanistic ideas such
as activation of protein kinase C, the role of
vascular endothelial growth factor (VEGF) and selective insulin resistance
as some of the basic mechanisms for the pathogenesis of diabetic microvascular and cardiovascular diseases which are now widely studied by multiple laboratories.
The drug, marketed
as Lucentis, targets a molecule called
vascular endothelial growth factor (VEGF), a key player in the
growth of blood vessels.
This activates the mast cells in these organs so that they undergo degranulation, releasing ready - made proteases such
as chymase and tryptase, and synthesizing inflammatory mediators (leukotrienes and
vascular endothelial cell
growth factor [VEGF]-RRB-.